Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Value Proposition and Innovative Models for Multi-Sectoral Engagement in Global Health PROCEEDINGS OF A WORKSHOP Liza Hamilton and Melissa Maitin-Shepard, Rapporteurs Forum on PublicâPrivate Partnerships for Global Health and Safety Board on Global Health Health and Medicine Division
THE NATIONAL ACADEMIES PRESSâ 500 Fifth Street, NWâ Washington, DC 20001 This activity was supported by contracts between the National Academy of Sciences and Anheuser-Busch InBev; Becton, Dickinson and Company; Bill & Melinda Gates Foundation; Catholic Health Association of the United States; ExxonMobil; Global Health Innovative Technology Fund; Intel Corporation; Johnson & Johnson; Medtronic; Merck & Co., Inc.; Novartis Foundation; PATH; Procter & Gamble Company; Safaricom; United Nations Foundation; University of Notre Dame; The UPS Foundation; U.S. Agency for International Develop- ment; U.S. Centers for Disease Control and Prevention; and U.S. Department of State. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. International Standard Book Number-13:â 978-0-309-49483-0 International Standard Book Number-10:â 0-309-49483-4 Digital Object Identifier:â https://doi.org/10.17226/25501 Additional copies of this publication are available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu. Copyright 2020 by the National Academy of Sciences. All rights reserved. Printed in the United States of America Suggested citation: National Academies of Sciences, Engineering, and Medicine. 2020. Value proposition and innovative models for multi-sectoral engagement in global health: Proceedings of a workshop. Washington, DC: The National Academies Press. https://doi.org/10.17226/25501.
The National Academy of Sciences was established in 1863 by an Act of Congress, signed by President Lincoln, as a private, nongovernmental institu- tion to advise the nation on issues related to science and technology. Members are elected by their peers for outstanding contributions to research. Dr. Marcia McNutt is president. The National Academy of Engineering was established in 1964 under the char- ter of the National Academy of Sciences to bring the practices of engineering to advising the nation. Members are elected by their peers for extraordinary contributions to engineering. Dr. John L. Anderson is president. The National Academy of Medicine (formerly the Institute of Medicine) was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues. Members are elected by their peers for distinguished contributions to medicine and health. Dr. Victor J. Dzau is president. The three Academies work together as the National Academies of Sciences, Engineering, and Medicine to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The National Academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine. Learn more about the National Academies of Sciences, Engineering, and Medicine at www.nationalacademies.org.
Consensus Study Reports publishedÂ by the National Academies of Sciences, Engineering, and MedicineÂ document the evidence-based consensusÂ on the studyâs statement of task by an authoring committee of experts.Â Reports typically include findings, conclusions, and recommendations based on information gathered by the committee and the committeeâs deliberations. Each report has been subjected to a rigorous and independent peer-review process and it representsÂ theÂ positionÂ ofÂ the National Academies on the statement of task. ProceedingsÂ publishedÂ by the National Academies of Sciences, Engineering, and MedicineÂ chronicle the presentations and discussions at a workshop, symposium, or otherÂ eventÂ convened by the National Academies. The statements and opinions contained in proceedings are those of the participants and are not endorsed by other participants, the planning committee, or the National Academies. For information about other products and activities of the National Academies, please visitÂ www.nationalacademies.org/about/whatwedo.
PLANNING COMMITTEE ON VALUE PROPOSITION AND INNOVATIVE MODELS FOR MULTI-SECTORAL ENGAGEMENT IN GLOBAL HEALTH1 CLARION JOHNSON (Co-Chair), Private Consultant, ExxonMobil SEEMA KUMAR (Co-Chair), Vice President, Innovation, Global Health, and Science Policy Communication, Johnson & Johnson CARA BRADLEY, Chief Corporate Engagement Officer, PATH BRENDA D. COLATRELLA, Associate Vice President, Corporate Responsibility; President, Merck Foundation; President, Merck Patient Assistance Program, Merck & Co., Inc. JAMES COUGHLAN, Loaned Executive, The UPS Foundation GABRIELLA MORRIS, Senior Vice President, Strategic Partnerships and UNICEF Ventures, U.S. Fund for UNICEF SHAWN STANDRIDGE, Corporate Medical Director, Procter & Gamble Company MARY LOU VALDEZ, Associate Commissioner, International Programs; Director, Office of International Programs, U.S. Food and Drug Administration Consultant to the Committee HANNAH KETTLER, Senior Program Officer, Life Sciences Partnerships, Bill & Melinda Gates Foundation 1â The National Academies of Sciences, Engineering, and Medicineâs planning commit- tees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for this published Proceedings of a Workshop rests with the workshop rapporteurs and the institution. v
FORUM ON PUBLICâPRIVATE PARTNERSHIPS FOR GLOBAL HEALTH AND SAFETY1 JO IVEY BOUFFORD (Co-Chair), Clinical Professor, New York University College of Global Public Health CLARION JOHNSON (Co-Chair), Private Consultant, ExxonMobil ANN AERTS, Head, Novartis Foundation SIR GEORGE ALLEYNE, Director Emeritus, Pan American Health Organization; Chancellor Emeritus, University of the West Indies NATASHA BILIMORIA, Director, U.S. Strategy, Gavi, the Vaccine Alliance DEBORAH L. BIRX, U.S. Global AIDS Coordinator and U.S. Special Representative for Global Health Diplomacy, The U.S. Presidentâs Emergency Plan for AIDS Relief (PEPFAR), U.S. Department of State SIMON BLAND, Director, New York Liaison Office, UNAIDS CARA BRADLEY, Chief Corporate Engagement Officer, PATH STEPHEN CHEGE, Director, Corporate Affairs, Safaricom ROBERT CLAY, Vice President, Save the Children BRENDA D. COLATRELLA, Associate Vice President, Corporate Responsibility; President, Merck Foundation; President, Merck Patient Assistance Program, Merck & Co., Inc. BRUCE COMPTON, Senior Director of International Outreach, Catholic Health Association of the United States KATE DODSON, Vice President for Global Health Strategy, United Nations Foundation RENUKA GADDE, Vice President, Global Health, Becton, Dickinson and Company ROGER GLASS, Director, Fogarty International Center ALLISON GOLDBERG, Executive Director, Anheuser-Busch InBev Foundation TREVOR GUNN, Vice President, International Relations, Medtronic (until March 2019) JESSICA HERZSTEIN, Preventive Medicine Specialist JAMES JONES, Executive Director, ExxonMobil Foundation SEEMA KUMAR, Vice President, Innovation, Global Health, and Science Policy Communication, Johnson & Johnson REBECCA MARTIN, Director of the Center for Global Health, U.S. Centers for Disease Control and Prevention 1â The National Academies of Sciences, Engineering, and Medicineâs forums and roundta- bles do not issue, review, or approve individual documents. The responsibility for this pub- lished Proceedings of a Workshop rests with the workshop rapporteurs and the institution. vii
EDUARDO MARTINEZ, President, The UPS Foundation, and Chief Diversity & Inclusion Officer, UPS JOHN MONAHAN, Senior Fellow and Senior Advisor for Global Health Initiatives to the President, Georgetown University GABRIELLA MORRIS, Senior Vice President, Strategic Partnerships and UNICEF Ventures, U.S. Fund for UNICEF ANDRIN OSWALD, Director, Life Sciences Partnerships, Bill & Melinda Gates Foundation REGINA RABINOVICH, ExxonMobil Malaria Scholar in Residence, Harvard T.H. Chan School of Public Health, Harvard University SCOTT C. RATZAN, Senior Fellow, Mossavar-Rahmani Center for Business and Government, Harvard Kennedy School BT SLINGSBY, Chief Executive Officer and Executive Director, Global Health Innovative Technology Fund (until December 2018) KATHERINE TAYLOR, Associate Director and Director, Global Health Training, Eck Institute for Global Health, University of Notre Dame TADATAKA âTACHIâ YAMADA, Venture Partner, Frazier Healthcare Partners Health and Medicine Division Staff RACHEL M. TAYLOR, Senior Program Officer and Forum Director (until December 2018) LIZA RENEE HAMILTON, Program Officer and Forum Director (from March 2019) KATHERINE PEREZ, Research Associate CLAIRE MOERDER, Senior Program Assistant (from March 2019) DANIEL CESNALIS, Financial Associate (until June 2019) JULIE PAVLIN, Director, Board on Global Health Consultant MELISSA MAITIN-SHEPARD, Rapporteur viii
Reviewers This Proceedings of a Workshop was reviewed in draft form by indi- viduals chosen for their diverse perspectives and technical expertise. The purpose of this independent review is to provide candid and critical comments that will assist the National Academies of Sciences, Engineer- ing, and Medicine in making each published proceedings as sound as possible and to ensure that it meets the institutional standards for quality, objectivity, evidence, and responsiveness to the charge. The review com- ments and draft manuscript remain confidential to protect the integrity of the process. We thank the following individuals for their review of this proceedings: BRIAN BRINK, Discovery Limited RENUKA GADDE, Becton, Dickinson and Company JOHN T. MONAHAN, Georgetown University Although the reviewers listed above provided many constructive comments and suggestions, they were not asked to endorse the content of the proceedings nor did they see the final draft before its release. The review of this proceedings was overseen by HUGH H. TILSON, University of North Carolina. He was responsible for making certain that an independent examination of this proceedings was carried out in accordance with standards of the National Academies and that all review comments were carefully considered. Responsibility for the final content rests entirely with the rapporteurs and the National Academies. ix
Acknowledgments A number of individuals contributed to the development of this workshop and proceedings. These include a number of staff members from the Health and Medicine Division and the National Academies of Sciences, Engineering, and Medicine: Jeanay Butler, Daniel Cesnalis, Liza Hamilton, Claire Moerder, Julie Pavlin, Katherine Perez, Bettina Seliber, Rachel M. Taylor, and Taryn Young. The planning committee contributed several hours of service to develop and execute the agenda. Reviewers also provided thoughtful remarks on the draft manuscript. The overall successful functioning of the Forum on PublicâPrivate Partnerships for Global Health and Safety (PPP Forum) and its activities depends on the generosity of its sponsors. Financial support for the PPP Forum is provided by Anheuser-Busch InBev; Becton, Dickinson and Company; Bill & Melinda Gates Foundation; Catholic Health Association of the United States; ExxonMobil; Global Health Innovative Technology Fund; Intel Corporation; Johnson & Johnson; Medtronic; Merck & Co., Inc.; Novartis Foundation; PATH; Procter & Gamble Company; Safaricom; United Nations Foundation; University of Notre Dame; The UPS Founda- tion; U.S. Agency for International Development; U.S. Centers for Disease Control and Prevention; and U.S. Department of State. xi
Contents ACRONYMS AND ABBREVIATIONS xvii 1 INTRODUCTION 1 Organization of the Proceedings, 4 2 MODELS FOR MULTI-SECTORAL ENGAGEMENT IN GLOBAL HEALTH: CHALLENGES AND OPPORTUNITIES 7 Value Proposition and Models, 8 Discussion, 10 3 MULTI-SECTORAL ENGAGEMENT IN GLOBAL HEALTH: A PERSPECTIVE FROM INDUSTRY LEADERSHIP 13 Value Proposition for Industry Engagement in Global Health and Safety, 14 Discussion, 23 4 VALUE PROPOSITION FOR MULTI-SECTORAL ENGAGEMENT IN GLOBAL HEALTH 25 Exploring Reasons for Private-Sector Engagement, 26 Panel Discussion, 29 Audience Discussion, 32 Small Table Discussions: Incentives and Barriers for Engaging in Global Health Through Multi-Sectoral Models, 34 xiii
xiv CONTENTS 5 APPROACHES AND MODELS FOR MULTI-SECTORAL ENGAGEMENT 39 Organizational Approaches for Multi-Sectoral Engagement, 41 Discussion, 49 Models of Multi-Sectoral Engagement and Value Creation, 53 Audience Discussion, 61 6 INNOVATION IN MULTI-SECTORAL ENGAGEMENT IN GLOBAL HEALTH 67 Collaboration and Expansion in the Use of Drone Technology for Global Health, 68 Expanded Special Project for Elimination of Neglected Tropical Diseases, 70 Digital Square, 73 Discussion, 76 Small Group Discussions, 78 7 CLOSING REMARKS 81 Key Messages from the Workshop and Priority Actions and Strategies, 82 Suggestions for Dissemination, 85 APPENDIXES A References 87 B Workshop Agenda 89 C Speaker and Moderator Biographical Sketches 97
Boxes and Figures BOXES 1-1 Statement of Task, 3 4-1 Objectives for Session 1: Value Proposition for Multi-Sectoral Engagement in Global Health, 26 4-2 Questions for Small Table Discussion Session on Incentives and Barriers for Engaging in Global Health Through Multi-Sectoral Models, 35 5-1 Objectives for Session 2: Approaches and Models for Multi- Sectoral Engagement, 40 6-1 Objectives for Session 3: Innovation in Multi-Sectoral Engagement in Global Health, 68 6-2 Questions for Facilitated Discussion on Innovative Models for Multi-Sectoral Engagement in Global Health, 79 7-1 Objectives for Session 4: Actionable Recommendations for the Way Forward, 82 xv
xvi BOXES AND FIGURES FIGURES 3-1 CD4 cell recovery following treatment, 17 3-2 Predicted sick days in the absence of treatment, 17 3-3 Cumulative per patient difference in sick days between treated and modeled untreated, 18 3-4 TB incidence by CD4 count, 18 3-5 Road traffic death rate per 100,000 population, 20 3-6 Driver behavior as cause for accidents and fatalities, 20 3-7 Driving behavior, 21 5-1 UNICEF and Gates Foundation shared goals and partnership framework, 46 5-2 MMV-supported projects in 1999, 55 5-3 MMV-supported projects in 2018, 55
Acronyms and Abbreviations AMFm Affordable Medicines Facilityâmalaria APC advance purchase commitment APOC African Programme for Onchocerciasis Control CEO chief executive officer CMMB Catholic Medical Mission Board DIAL Digital Impact Alliance DNDi Drugs for Neglected Diseases initiative ESPEN Expanded Special Project for Elimination of Neglected Tropical Diseases FDA U.S. Food and Drug Administration FENSA Framework for Engagement with Non-State Actors GARDP Global Antibiotic Research and Development Partnership IFC International Finance Corporation LMIC low- and middle-income country xvii
xviii ACRONYMS AND ABBREVIATIONS MMV Medicines for Malaria Venture MSF MÃ©decins Sans FrontiÃ¨res (Doctors Without Borders) NCD noncommunicable disease NGO nongovernmental organization PDP product development partnership PEPFAR The U.S. Presidentâs Emergency Plan for AIDS Relief PPP publicâprivate partnership PPP Forum Forum on PublicâPrivate Partnerships for Global Health and Safety PRC Peer Review Committee R&D research and development RUTF ready-to-use therapeutic food SDG Sustainable Development Goal TB tuberculosis TDR Special Programme for Research and Training in Tropical Diseases UHC universal health coverage UNICEF United Nations Childrenâs Fund UPS United Parcel Service USAID U.S. Agency for International Development WHO World Health Organization